This inventor holds 4 USPTO granted patents, plus 3 CIPO patents. Top assignees: Ogd2 Pharma, The University of Nantes. Active years: 2018-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 6 
3 out of 156 
Years Active: 2018-2020
Title: Innovations by Inventor Mickael Terme
Introduction
Mickael Terme is a notable inventor based in Nantes, France. He has made significant contributions to the field of cancer research through his innovative patents. With a total of 4 patents, his work focuses on therapeutic and diagnostic strategies for cancer treatment.
Latest Patents
Mickael Terme's latest patents include groundbreaking methods for targeting the O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer. This patent describes an antibody that recognizes the O-acetylated-GD2 ganglioside, aimed at treating Cancer Stem Cells (CSC) cancer. The patent outlines a pharmaceutical composition that includes the antibody for treating CSC cancer and a method for administering the antibody to patients in need. Additionally, it describes a method for diagnosing CSC, utilizing the O-acetylated-GD2 ganglioside as a biomarker, and a method for predicting a subject's response to treatment with the antibody or composition.
Another significant patent involves a human IgG1 derived antibody with pro-apoptotic activity. This patent details a method for enhancing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody. The method includes mutating the human CH1 domain to restore the pairing between CH1 and CL domains, or substituting the CH1 domain with that from other IgG subclasses. The resulting antibody includes specific amino acid sequences for both light and heavy chains, enhancing its effectiveness in targeting antigens.
Career Highlights
Mickael Terme has worked with notable organizations such as Ogd2 Pharma and Université de Nantes. His experience in these institutions has contributed to his expertise in the field of immunology and cancer research.
Collaborations
Mickael has collaborated with professionals like Mylene Dorvillius and Jean-Marc Le Doussal, further enriching his research and development efforts in innovative cancer therapies.
Conclusion
Mickael Terme's contributions to cancer research through his patents demonstrate his commitment to advancing therapeutic strategies. His innovative work continues to pave the way for new diagnostic and treatment options in the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile